Gynecologic Cancer News

Breast cancer and cervical cancer screenings declined sharply during the early part of the COVID-19 pandemic, according to CDC data released today.

In this video, Janos L. Tanyi, MD, PhD, discussed findings from the “very interesting” VITAL study that assessed the potential of a novel vaccine as front-line maintenance therapy for women with ovarian cancer.

Patients with HF had elevated risk for various cancer diagnoses vs. those without HF, especially cancers of the head and neck and respiratory organs.

In this video, Janos L. Tanyi, MD, PhD, assistant professor in the department of gynecologic oncology at the University of Pennsylvania, spoke with Healio about a study evaluating the use of mirvetuximab soravtansine for recurrent ovarian cancer.

In this video, Janos L. Tanyi, MD, PhD discussed findings from a study evaluating pafolacianine sodium combined with intraoperative near-infrared fluorescence imaging in patients with ovarian cancer.

In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, spoke with Healio about research that demonstrated the potential of a novel vaccine as front-line maintenance therapy in advanced-stage ovarian cancer.

In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, discussed “hotly anticipated” results from the BOOST trial evaluating the potential benefits of extending bevacizumab therapy plus chemotherapy in newly diagnosed ovarian cancer.

In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, spoke with Healio about the OUTBACK trial presented at the ASCO Annual Meeting.

A blood-based test demonstrated efficacy and high specificity in detecting multiple cancer types with diverse biological features, paving the way for a new screening option, according to research published in Annals of Oncology.

Nearly half of a geographically diverse cohort of women with gynecologic cancer reported financial toxicity, which appeared associated with cost-coping strategies, according to a study in International Journal of Gynecological Cancer.